Friday, May 9, 2025
5/9/2025
Defining the biologic and physiologic trajectory of presymptomatic through advanced pulmonary fibrosis - PROJECT SUMMARY/ABSTRACT Pulmonary fibrosis (PF) is prevalent among 200,000 persons in the USA, a figure that is increasing. Most individuals present with progressive dyspnea and/or cough, and have moderately advanced disease with irreversible fibrosis at the time of diagnosis. Treatment of PF at an earlier (pre-clinical) stage would result in a greater reduction in the overall burden of morbidity, but limited understanding of the early natural history, including the biological and clinical progression, remains a barrier to accomplishing this goal. To improve the understanding of the earliest stages of PF, >450 asymptomatic relatives of persons with familial PF have undergone serial screening high resolution CT (HRCT) scans to detect pre-clinical PF, as part of an ongoing prospective cohort study. When defined by the new development or progression of abnormal changes of the pulmonary parenchyma (“interstitial lung abnormalities” [ILA]), pre-clinical PF is observed in approximately 20% of participants. While having ILA on the first screening HRCT is a major risk factor for progression, almost half of pre-clinical PF comprised new development of ILA, underscoring the need for additional biomarkers of early disease. Altered gene expression in the peripheral blood precedes pre-clinical progression in this cohort, and may represent a promising biomarker. Clinically, among those participants progressing through pre-clinical PF (toward clinically-diagnosed PF), the observed pattern of progressive physiologic decay appears to be disease stage-specific and occurs in a manner that may be shared across individuals with PF. Importantly, the forced vital capacity (FVC) undergoes very little change during pre-clinical PF. The FVC is used to monitor for PF progression and has been the primary endpoint in successful trials of disease modifying therapy for PF. Therefore, alternative endpoints/outcome measures are needed in order to study disease modification in pre- clinical PF. The overall hypothesis is that PF follows a sequenced progression, including blood biomarkers (transcriptomic and/or proteins) indicative of early pathobiology and predictive of pre-clinical progression, and a stage-specific, sequenced decay in key physiologic parameters. The following Specific Aims are proposed: (1) Define a blood biomarker signature to predict progressive pre-clinical PF; and (2) Develop a disease progression model (DPM) to describe the physiologic decay across all stages of PF. Disease-specific DPMs have been used to measure disease modification such that detection of a treatment effect is subject-specific, a more powerful alternative to analysis without regard to stage-specific progression expectations. The working hypotheses will be tested during continued observation of the prospective pre-clinical PF cohort and several cohorts of patients with established PF. Completion of these Aims is an important step toward a long-term programmatic goal (of the investigators and the NHLBI) to speed development of new disease modifying therapy for PF, particularly those capable of preventing or delaying symptom onset.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).